Get the Stockscreener App
4.61
2.54%
-0.12
Lexeo Therapeutics Inc stock is traded at $4.61, with a volume of 552.78K.
It is down -2.54% in the last 24 hours and up +9.24% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$4.73
Open:
$4.52
24h Volume:
552.78K
Relative Volume:
0.79
Market Cap:
$153.04M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-1.6276
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
+11.62%
1M Performance:
+9.24%
6M Performance:
-15.10%
1Y Performance:
-64.70%
1-Day Range:
$4.28
$4.78
1-Week Range:
$3.91
$5.0594
52-Week Range:
$1.45
$13.63
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.61 | 255.33M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
How does Lexeo Therapeutics Inc. compare to its industry peersDaily Trading Recommendation For Smart Trading - jammulinksnews.com
What are the technical indicators suggesting about Lexeo Therapeutics Inc.Financial News Updates For Consistent Profits - jammulinksnews.com
What are analysts’ price targets for Lexeo Therapeutics Inc. in the next 12 monthsDaily Trading Strategy For Smart Trading - jammulinksnews.com
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Oppenheimer Initiates Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Lexeo Therapeutics Initiates Coverage: Oppenheimer Outperform Rating with $20 PT - AInvest
Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating - Investing.com Australia
Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Should I hold or sell Lexeo Therapeutics Inc. stock in 2025Advanced Screener Ideas For Fast Growth - jammulinksnews.com
What is Lexeo Therapeutics Inc. company’s growth strategyDaily Trading Picks With High Returns - jammulinksnews.com
Candlestick Reversal Detected on Lexeo Therapeutics Inc.’s ChartPotential Breakout Stock List Published This Week - metal.it
Lexeo Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowGrowth Based Stock Signal Screener Updated - metal.it
11 Best New Penny Stocks to Buy Right Now - Insider Monkey
Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - Yahoo Finance
How did LXEO's operating expenses trend in Q4 2024? - AInvest
What is the risk reward ratio of investing in Lexeo Therapeutics Inc. stockWealth Building Data Feed For Every Investor - jammulinksnews.com
Does Lexeo Therapeutics Inc. stock perform well during market downturnsDiscover high-growth stocks for your portfolio - jammulinksnews.com
How many analysts rate Lexeo Therapeutics Inc. as a “Buy”Boost your returns with professional guidance - jammulinksnews.com
Is it the right time to buy Lexeo Therapeutics Inc. stockCapitalize on market trends before they peak - jammulinksnews.com
Will Lexeo Therapeutics Inc. stock split in the near futureFree Smart Money Stock Analysis - metal.it
When is Lexeo Therapeutics Inc. stock expected to show significant growthProven strategies for superior portfolio growth - jammulinksnews.com
What are Lexeo Therapeutics Inc. company’s key revenue driversBuild wealth with reliable stock picks - jammulinksnews.com
Why is Lexeo Therapeutics Inc. stock attracting strong analyst attentionRapid-fire capital growth - jammulinksnews.com
How volatile is Lexeo Therapeutics Inc. stock compared to the marketCapitalize on high-yield stocks early - jammulinksnews.com
What makes Lexeo Therapeutics Inc. stock price move sharplyAchieve breakthrough investment performance - jammulinksnews.com
What is the dividend policy of Lexeo Therapeutics Inc. stockHigh-performance investment picks - jammulinksnews.com
Lexeo Therapeutics Inc. Stock Analysis and ForecastUnstoppable profit momentum - Autocar Professional
Is Lexeo Therapeutics Inc. a good long term investmentExtraordinary profit generation - Autocar Professional
What risks could impact Lexeo Therapeutics Inc. stock performanceDynamic investment growth - jammulinksnews.com
What analysts say about Lexeo Therapeutics Inc. stockPowerful market insights - PrintWeekIndia
What drives Lexeo Therapeutics Inc. stock priceFree Stock Market Return Analysis - Autocar Professional
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
May 16 '25 |
Sale |
2.77 |
585 |
1,623 |
67,681 |
| Robertson Jenny | Chief Legal Officer |
May 16 '25 |
Sale |
2.77 |
521 |
1,445 |
63,098 |
| See Tai Sandi | Chief Development Officer |
May 16 '25 |
Sale |
2.77 |
367 |
1,018 |
59,242 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):